Clinical Trial Update: Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of adagrasib (MRTX849) with or without nivolumab in resectable non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Krazati (adagrasib) (adagrasib)
• Opdivo (nivolumab) (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Resectable Non-Small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN